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Relaxin-3The nucleus incertus (NI), located in the caudal brainstem, mainly consists of GABAergic neurons with
widespread projections across the brain. It is the chief source of relaxin-3 in the mammalian brain and densely
expresses corticotropin-releasing factor type 1 (CRF1) receptors. Several other neurotransmitters, peptides and
receptors are reportedly expressed in the NI. In the present investigation, we show the expression of dopamine
type-2 (D2) receptors in the NI by reverse transcriptase-polymerase chain reaction (RT-PCR), western blotting
(WB) and immunoﬂuorescence (IF). RT-PCR did not show expression of D3 receptors. D2 receptor short isoform
(D2S)-like, relaxin-3, CRF1/2 receptor and NeuN immunoreactivity were co-expressed in the cells of the NI.
Behavioural effects of D2 receptor activation by intra-NI infusion of quinpirole (a D2/D3 agonist) were evaluated.
Hypolocomotion was observed in home cage monitoring system (LABORAS) and novel environment-induced
suppression of feeding behavioural paradigms. Thus the D2 receptors expressed in the NI are likely to play a
role in locomotion. Based on its strong bidirectional connections to themedian raphe and interpeduncular nuclei,
the NI was predicted to play a role inmodulating behavioural activity and the present results lend support to this
hypothesis. This is the ﬁrst evidence of expression of a catecholamine receptor, D2-like immunoreactivity, in the
NI.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The nucleus incertus (NI) is a highly conserved brainstem structure
present in invertebrates, rodents, non-human primates and humans.
It is located at the base of the fourth ventricle and consists of
long GABAergic projection neurons with widespread connections
throughout the rat brain [21,45]. Strong inputs from the prefrontalology, Yong Loo Lin School of
l Drive, National University of
.
ce Program, Yale University,
. This is an open access article undercortex, motor cortex, lateral habenula, oculomotor control regions and
medial septum to the NI indicate a role in integrating information to
modulate behavioural activity possibly exerted through its major effer-
ent connections to the median raphe, interpeduncular nucleus, and
hippocampal system [21,52]. The NI is the main neuronal source of the
neuropeptide relaxin-3 that is known to be involved in various behav-
iours associated with anxiety, fear, arousal, stress response, reward,
addiction, cognition, memory and feeding (for review see: [52,55,59]).
For a small group of neurons, the NI expresses a variety of receptors:
CRF1 receptors at high density, GABA receptors, 5-HT receptors, cholin-
ergic receptors and orexin receptors [4,22,29,40,48,61]. However,
dopamine receptors have not previously been discovered in the NI.
D2 receptors bind to Gαi/o and inhibit adenylyl cyclase, in turn
reducing cAMP levels [2]. Alternative splicing of a 29 amino acid regionthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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long (D2L) and short (D2S) [10,20,26,27,41]. This region has been found
to be important in G-protein coupling thus resulting in distinct func-
tional roles of the two isoforms ([17]; for review see: [11]). D2 receptors
are highly expressed in the striatum, nucleus accumbens and olfactory
tubule; and moderately expressed in the substantia nigra, ventral
tegmental area, prefrontal cortex, amygdala, hippocampus and hypo-
thalamus of rodents [11,64]. In the brainstem, certain nuclei strongly ex-
press D2 receptors, including the locus coeruleus, trigeminal nucleus
and the nucleus of the solitary tract [64].
Our previously published work showed that both typical and atypi-
cal antipsychotics induced signiﬁcant c-Fos expression in the NI [50].
Since the main underlying mechanism of action of antipsychotics is D2
receptor antagonism-mediated, these ﬁndings prompted us to investi-
gate the presence of D2 receptors in the NI. In the present manuscript,
reverse transcription polymerase chain reaction (RT-PCR), western
blotting and immunoﬂuorescence labelling techniques have been
employed to show the expression of D2 receptors in the NI. Concurrent
immunoﬂuorescent labelling of NeuN, CRF1 and relaxin-3 was carried
out to validate the location of the NI and study receptor co-expression
patterns. To further conﬁrm the presence of D2 receptors, quinpirole
(a D2/D3 agonist) was microinfused into the NI and the rats were ex-
posed to the Laboratory Animal Behaviour Observation Registration
and Analysis System (LABORAS) home cage monitoring system and a
novel environment-induced suppression of feeding paradigm.2. Materials and methods
2.1. Animals
Forty-six male Sprague–Dawley rats (280–350 g), obtained from
the Laboratory Animals Centre, National University of Singapore, were
utilised in this investigation. The procedures conductedwere in compli-
ance with the guidelines of the National Institutes of Health Guide
for Care and Use of Animals, and with approval from the Institutional
Animal Care and Use Committee (IACUC) of the National University of
Singapore. Rats were housed in pairs in individually ventilated cages
that were maintained in a temperature controlled room (22 °C–24 °C)
with a 12 hour light–dark cycle. The animals were given ad libitum ac-
cess to food andwater and were acclimatised to the housing conditions
for at least 5 days.2.2. Drugs
Quinpirole hydrochloride (Tocris, UK), ketamine (Parnell
Manufacturing Pty Ltd.; Alexandria, NSW, Australia), xylazine
(Ilium Xylazil, Troy Laboratories Pty Ltd.; Glendenning, NSW,
Australia), enroﬂoxacin (Baytril 5%, Bayer Health Care; Seoul,
Korea) and carprofen (Carprieve, Norbrook Laboratories (GB),
Ltd.; Carlisle, UK) were freshly prepared in sterile isotonic saline
(B. Braun, Germany) before use. Pentobarbital (Valabarb) was
purchased from Jurox Pty Ltd., Australia.2.3. Fresh tissue harvest
Ratswere anaesthetisedwith a pentobarbital overdose and decapitat-
ed. The brains were removed immediately and 500 μm sections were
collected with a rat brain matrix (Roboz Surgical, USA). The position of
the NI (Fig. 1A) was veriﬁed by light microscopy and punched out using
a micropunch (0.75 mm, Sigma-Aldrich, USA) as described previously
[30]. NI tissue punches and microdissected regions of the caudate
putamen were homogenised for RT-PCR ampliﬁcation and western blot
analysis.2.4. RNA extraction and reverse transcription PCR (RT-PCR)
Total RNA was extracted from the rats' NI or striatum and puriﬁed
with the Purelink Mini Total RNA Puriﬁcation kit (Invitrogen, USA)
according to the manufacturer's guidelines. The amount of RNA was
quantiﬁed and approximately 1 μg of RNA was reverse transcribed
with oligo (dT) primers using ImProm-II™ Reverse Transcription
system. The PCR reaction for the dopamine receptor subtypes [63] and
β-actin was carried out with the following sets of primers: D2 forward
primer 5′-GCA GTC GAG CTT TCA GAG CCA ACC TG-3′, reverse primer
5′-AGA ACT TGG CAA TCC TGG GAT TGA C-3′ (255 bp expected band
size for short isoform and 342 bp expected band size for long isoform);
D3 forward primer 5′-GTG ACT GTC CTG GTC TAT GCC AG-3′, reverse
primer 5′-GCA GAT GCT GTA GTA GCG CTT CAG-3′ (312 bp expected
band size) and β-actin forward primer 5′-ATC CTG AAA GAC CTC TAT
GC-3′, reverse primer 5′-AAC GCA GCT CAG TAA CAG TC-3′ (287 bp
expected band size). The PCR cycling reactions were carried out at 94 °C
for 5 min, 30 cycles of 94 °C for 30 s, 58 °C–65 °C for 1 min, 72 °C for
1 min followed by 10 min at 72 °C. The ampliﬁed products were
separated in 1.5% agarose gel, and then visualized under UV irradiation.
2.5. Western blotting
FreshNI tissuewas dissected and lysedwith radioimmunoprecipitation
assay (RIPA) buffer (150 mM sodium chloride, 1.0% Triton X-100,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 50 mM
Tris, pH 8.0). The total protein concentration was determined using
a Pierce bicinchoninic acid assay (BCA) kit (Pierce Biotechnology,
USA). 50 μg of protein was separated by 10% or 12% sodium dodecyl
sulphate SDS-PAGE for about 1.5 h and then electroblotted onto a
low immunoﬂuorescence PVDF membrane (Biorad, USA) at 100 mA
for 2 h. The membranes were subsequently blocked with 5% skim
milk, 5% bovine serum albumin (BSA) or 2% normal goat serum
(NGS) in Tris-buffered saline/Tween 20 (TBST) for an hour in room
temperature followed by incubation with primary antibodies:
anti-D2 (1:1000, Ab32349, Abcam, Hong Kong); anti-D2S (1:1000;
324,396, Merck Millipore, USA); anti-CRF RI/II (1:1000, Santa Cruz,
USA), anti-relaxin-3 (1:1000); or anti-β-actin (1:10,000, A-5441,
Sigma-Aldrich, USA) overnight at 4 °C. The mouse monoclonal anti-
relaxin-3 antibody was produced from hybridoma cells as previously
described [30]. Following primary antibody incubation, the blot was then
washed and incubated with a peroxidase-conjugated anti-goat (1:5000;
Pierce Biotechnology, USA), anti-mouse (1:5000; ThermoScientiﬁc,
USA) or anti-rabbit IgG (1:5000; Pierce Biotechnology, USA) for an hour
at room temperature with agitation. Protein bands were detected by
incubating the membranes with peroxidase substrate Luminata Forte
(Merck Millipore, USA) and imaging was conducted with a luminescent
image analyzer (Image Quant LAS 4000, GE Healthcare, UK). The
relaxin-3 blot was incubated with goat anti-mouse AlexaFluor488
(1:5000) for an hour at room temperature with agitation and the
ﬂuorescence signal was detected with the Image Quant LAS 4000.
2.6. Immunoﬂuorescence
Rats were anaesthetizedwith a pentobarbital overdose. Transcardial
perfusion was carried out with isotonic saline followed by 2%
paraformaldehyde in phosphate buffer (0.1 M). The brains were
subsequently post-ﬁxed in 2% paraformaldehyde at 4 °C for 2 h and
soaked in 15% sucrose followed by 30% sucrose at 4 °C for 2 days
each. Sections (30 μm) were collected serially in sterile PBS in a
cryostat (CM 3050, Leica Biosystems, Germany). The ventral half of
the brain sections containing the NI was stored in cryoprotectant
solution (1% PVP-10, 30% ethylene glycol, 30% sucrose, 50% 0.1 M
phosphate buffer, pH 7.4) at –20 °C until immunoﬂuorescence
labelling was conducted [24]. Sections were hydrated by washing
in phosphate buffered saline (PBS) and permeabilized by incubation
Fig. 1. (A) Schematic representation of a brainstem section in which the arrow points to two grey circles indicating the areas of tissue punched out for RT-PCR or western blot analysis.
(B) Schematic diagram of the novel environment-induced suppression of feeding arena. (C) Representative image showing the cannula position in the nucleus incertus. Arrow points
to the pontamine sky blue dye spot.
Fig. 2. (A) Agarose gel electrophoresis of PCR products of dopamine receptor D2 and D3 subtypes in the nucleus incertus. RT-PCR was conducted on total RNA extracted from the nucleus
incertus tissue of rats. Representative western blots showing the evidence of (B) D2R and relaxin-3 expression, (C) D2SR and relaxin-3 expression in the nucleus incertus (NI) and caudate
putamen (CP). Representative ﬂuorescencemicroscopy images showingD2 receptor-like immunoreactivity in the nucleus incertus (D) and caudate putamen (E). 4 V: fourth ventricle; Cx:
cortex; NIc: nucleus incertus pars compacta; NId: nucleus incertus pars dissipata. Scale bars: 100 μm.
527J.R. Kumar et al. / Physiology & Behavior 151 (2015) 525–534
Fig. 3. Representative confocal images showing that D2S receptor-like immunoreactivity in the nucleus incertus is co-expressed with CRF1/2 receptors. Figures A–F are confocal
images from the same tissue section. (A) and (D) show the expression of D2S receptor-like immunoreactivity (green) at lower and higher magniﬁcations (region boxed with dashed
line in C), respectively. (B) and (E) show the expression of CRF1/2 (red) at lower and higher magniﬁcations (region boxed with dashed line in C), respectively. (C) represents the
merge of (A) and (B). (F) Z-stack confocal image showing the co-localisation of D2S receptor-like immunoreactivity, CRF1/2 and DAPI (blue) in the nucleus incertus. Scale bars: 100 μm.
528 J.R. Kumar et al. / Physiology & Behavior 151 (2015) 525–534in 0.3% Triton-X 100 in PBS (PBST) for 10 to 30 min. The sections
were then incubated in 5% fetal bovine, goat or donkey serum for
1 h at room temperature followed by incubation in the following
primary antibody solutions for 24–72 h at 4 °C: anti-D2 (1:100,
Ab32349, Abcam, Hong Kong); anti-D2S (1: 150; 324,396, Merck
Millipore, USA); anti-CRF RI/II(1:600, Santa Cruz, USA); anti-relaxin-3
(1:100); and anti-NeuN (1:200, MAB 377, Merck Millipore, USA). The
mouse monoclonal anti-relaxin-3 antibody was produced from hybrid-
oma cells as previously described [30]. For the co-staining with
anti-relaxin-3 (raised in mouse) and anti-CRF RI/II (raised in goat),
anti-D2S (raised in rabbit) was used instead of anti-D2 (raised in goat)
due to compatibility of the antibody source. All sections were rinsed
in PBS prior to incubation in solutions containing appropriate Alexa
Fluor secondary antibodies (Invitrogen, Life Technologies, CA, USA) for
an hour at room temperature in the dark. All sections were rinsed
4 × 5 min each in PBS and mounted on glass slides. The sections were
gently shaken during all incubation periods including the rinses. The
sections were dried, covered with Prolong Antifade Gold reagent with
DAPI (Invitrogen, Life Technologies, CA, USA) and coverslipped. The sec-
tionswere viewed and photographedwith a confocalMicroscope (Zeiss
LSM 510 Meta, Zeiss, Germany) or a ﬂuorescence microscope (BX-51,
Olympus, Japan).
2.7. Intra-NI administration of quinpirole and behaviour
2.7.1. Surgery
Rats were anaesthetisedwith a cocktail of ketamine (75mg/kg) and
xylazine (10 mg/kg) injected intraperitoneally and mounted on to astereotaxic frame. The scalp was shaved and a midline sagittal incision
exposed the bare skull. A burr hole was drilled at AP: −9.7 mm, ML:
−0.1 mm from the bregma to target the nucleus incertus [46].
A guide cannula (Plastics One, USA) 8 mm in length was carefully
inserted to a depth of 7.4 mm from the skull surface and was held
in place with dental cement and anchoring screws ﬁtted to the skull.
The guide cannula was closed using a cap with a stylette. The rats
were then allowed a rehabilitation period of 1 week, with analgesic
(carprofen) and antibiotic (enroﬂoxacin) treatments injected
subcutaneously for the ﬁrst 5 days.2.7.2. General considerations for behavioural assessments
All behavioural assessments were conducted during the light phase
of the 12 h light–dark cycle. The NI cannula-implanted rats had free
access to water but food was restricted for 18 h prior to some of the ex-
periments as speciﬁed below. They were brought to the experimental
room at least 1 h before the commencement of behavioural assess-
ments. They were gently handled and quinpirole (6 μg/0.1 μl) or vehicle
(equivalent volume of sterile isotonic saline) was infused into the NI
over a period of 30 s into the brain. The administration was done
using an infusion cannula that had a 1 mm projection beyond the
guide cannula. The infusion cannula was left in place for 1 min before
re-capping and placing the rat in the exploration arenas. Behavioural
assessment began immediately. Behavioural apparatus was cleaned
with 70% ethanol between the trials. All the behavioural observations
were video recorded and analysed using a video tracking system
(Ethovision, version 8.2, Noldus, Netherlands).
Fig. 4. Representative confocal images showing that D2S receptor-like immunoreactivity in the nucleus incertus is co-expressed with relaxin-3. Figures A–F are confocal images from
the same tissue section. (A) and (D) show theexpression of D2S receptor-like immunoreactivity (red) at lower and highermagniﬁcations (region boxedwith dashed line inC), respectively.
(B) and (E) show the expression of relaxin-3 (green) at lower and highermagniﬁcations (region boxedwith dashed line in C), respectively. (C) represents themerge of (A) and (B). (F) Z-
stack confocal image showing the co-localisation of D2S receptor-like immunoreactivity, relaxin-3 and DAPI (blue) in the nucleus incertus. Scale bars: 100 μm.
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Cannula-implanted rats were fasted for 18 h and then acclimatised
to the experimental room for 1 h. Following intra-NI infusion of salineFig. 5. D2S receptor-like immunoreactivity, relaxin-3 and CRF1/2 are co-localised in many neu
immunoreactivity (red), (B) relaxin-3 (green) and (C) CRF1/2 (magenta) receptor expres
immunoreactivity, relaxin-3, CRF1/2 and DAPI (blue) in the nucleus incertus. D2S receptor-lik
(E) D2S receptor-like immunoreactivity (red), (F) NeuN expression (green) and (G) Z-stack sh
incertus. Scale bars: 100 μm.or quinpirole (6 μg/0.1 μl), the rats were individually placed in the Lab-
oratory Animal Behaviour Observation Registration and Analysis Sys-
tem (LABORAS, Metris, Netherlands) home cages, which were similarrons of the nucleus incertus. Representative confocal images show (A) D2S receptor-like
sion (C). (D) Z-stack confocal image showing the co-localisation of D2S receptor-like
e immunoreactivity is also shown to be co-localised with NeuN in the nucleus incertus.
owing the co-localisation of D2S receptor-like and NeuN immunoreactivity in the nucleus
Fig. 6. Intra-NI injectionof quinpirole (6 μg/0.1 μl) causes locomotor and exploratory deﬁcits in LABORAShomecage activity. Representative images of heatmapsof space utilisation showing the
behavioural activity of (A) saline and (B) quinpirole treated rats during a 2-hr observation period. Locations of feed andwater are schematically represented as rectangular zones (broken lines).
Regions with dark colour indicate least visits and those with light colour indicate higher visit frequency. Data points represent themean of the parameter over the preceding 5min (C–H). Col-
umns represent mean of values over 2 h and error bars represent SEM (insets in C–H). *P b 0.05, **P b 0.01, ***P b 0.001 compared to vehicle (sterile isotonic saline) treatment. Repeatedmea-
sures ANOVA followed by multivariate analysis. N = 6–10.
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rameters such as locomotion, velocity, distance travelled, feeding,
drinking, rearing and grooming were then continuously assessed for
2 h by the LABORAS software.
2.7.4. Novel environment-induced suppression of feeding
The behavioural assessment was carried out as per previously
published reports [7] with certain modiﬁcations as mentioned.
Cannula-implanted rats, fasted for 18 h, were acclimatised for 1 h in a
dimly lit experimental room. Feed pellets were placed in the centre of
the circular arena (diameter: 120 cm and height 50 cm, Fig. 1B) with a
dark ﬂoor and white coloured walls. The observation area was virtually
divided into zones, namely feed area, middle area and periphery in the
acquisition software (Ethovision Version 8). Rats were individually in-
fused with saline or quinpirole (6 μg/0.1 μl), placed in the periphery of
the arena and behaviour was monitored for 10 min. The latency to
enter the feed area and the durations of time spent in the feed area
and periphery weremeasuredwith the Ethovision behavioural tracking
and analysis software. The latency to feed was observed manually from
the video ﬁle by an experimenter blind to the treatment. The quantity of
food consumed and the number of faecal pellets left after each trialwere
also recorded.
2.7.5. Post-mortem analysis
The rats were anaesthetized with an overdose of pentobarbital and
0.1 μl of pontamine sky blue dye was infused into the NI via the guide
cannula in the same manner as the drug infusion described above.
Subsequently, transcardial perfusion was carried out with isotonic
saline followed by 4% paraformaldehyde in phosphate buffer (0.1 M).
The brains were subsequently post-ﬁxed in 4% paraformaldehyde at 4 °C
overnight and soaked in 30% sucrose at 4 °C for 2 days. Sections (30 μm)
were collected serially in PBS with a cryostat (CM 3050, Leica Biosystems,
Germany). The sectionswere then Nissl stained to identify the track of the
implanted cannula (Fig. 1C). Rats with incorrect cannula positions were
excluded from analysis.
2.7.6. Statistical analysis
All statistical analyses conducted were between-subjects. The
behavioural data from home cage monitoring (LABORAS) at various
time points was subjected to repeated measures ANOVA across time
followed by multivariate analysis to identify the differences at speciﬁc
time points. The data from other behavioural studies were subjected
to unpaired two-tailed Student's t-test. IBM SPSS version 20.0 software
package was used for the statistical analysis and the level of statistical
signiﬁcance was set at P b 0.05. The data are expressed asmean± SEM.
3. Results
3.1. Molecular biology
3.1.1. RT-PCR
The expression of D2 (long and short forms), but not D3 receptor
mRNA was evident in the triplicate NI samples (Fig. 2A).
3.1.2. Western blotting
The nonselective D2 receptor antibody recognizing the 1–100 amino
acids of the humanD2 receptor, produced a band at ~105 kDa present in
both the NI sample and the caudate putamen (Fig. 2B). This band is
likely to be the D2 receptor dimer [31]. Using an antibody selective for
the short isoform of the D2 receptor, the strongest band was ~41 kDa,
which is the expected weight for the glycosylated D2S receptor. This
band is strongly expressed in the NI and caudate putamen (Fig. 2C).
The strong relaxin-3 bands (Fig. 2B and C) present in the NI samples
validated the position of the NI microdissection.3.1.3. Immunoﬂuorescence
Immunoﬂuorescence with the non-selective D2 receptor antibody
showed D2 receptor-like immunoreactivity in the NI (Fig. 2D) and in
the caudate putamen region, which was used as the positive control
(Fig. 2E). Asmentioned earlier, the co-expression studieswere conduct-
ed with D2S due to the compatibility of the antibodies. Robust D2S
receptor-like immunoreactivity was found in the NI. D2S positive
neurons of the NI co-expressed CRF1/2 receptors (Fig. 3) and
relaxin-3 (Fig. 4). Triple immunoﬂuorescence labelling showed the
co-expression of D2S, CRF1/2 and relaxin-3 in several NI neurons
(Fig. 5A–D). The D2S positive cells also co-labelled for NeuN (Fig. 5E–G)
conﬁrming the expression of D2S receptor-like immunoreactivity
in neurons.
3.2. Behaviour
3.2.1. Home cage exploration
Heat maps of space utilisation within the home cage showed
hypolocomotion after intra-NI quinpirole treatment (Fig. 6A,B).
Repeated measures ANOVA on the data across time showed signiﬁ-
cant changes in distance travelled (F23,322 = 16.427, P b 0.0001),
time spent in locomotion (F23,322 = 21.213, P b 0.0001), time
spent in rearing (F23,322 = 14.864, P b 0.0001), time spent in
grooming (F23,322 = 4.560, P b 0.0001), time spent in feeding
(F23,322 = 4.571, P b 0.0001) and frequency of feeding (F23,322 =
4.216, P b 0.0001). Intra-NI quinpirole (6 μg) signiﬁcantly reduced
distance travelled (F1,14 = 6.962, P = 0.019), duration of time
spent in locomotion (F1,14 = 1.286, P = 0.001) and rearing (F1,14 =
6.958, P = 0.019) compared to saline infusion (Fig. 6C–F). Other pa-
rameters, grooming (F1,14 = 2.304, P = 0.151, NS), feeding duration
(F1,14 = 1.823, P = 0.198, NS), and feeding frequency (F1,14 = 1.829,
P = 0.198, NS), were not signiﬁcantly affected by intra-NI quinpirole
administration (Fig. 6C–H).
3.2.2. Novel environment-induced suppression of feeding
Two-tailed unpaired t-test on the data revealed that infusion of
quinpirole (6 μg/0.1 μl) into the NI suppressed the distance travelled
(P = 0.001), velocity of the rat movement (P = 0.001), frequency of
visits to the central feed area (P = 0.004), duration of time spent in
the feed area (P = 0.007), quantity of feed consumed (P = 0.022),
increased latency to visit feed area (P = 0.021), and latency to feed
(P= 0.002) compared to the saline infusion (Fig. 7A–G). Thigmotax-
is (measured by the duration of time spent close to the wall) and
defecation were signiﬁcantly greater in the quinpirole infused rats
(P = 0.0002 and P = 0.026, respectively) than saline infused rats
(Fig. 7H and I).
4. Discussion
The presence of D2 receptors in the NI is demonstrated through RT-
PCR, western blotting and immunoﬂuorescence labelling techniques
and further conﬁrmed by studying the effect of quinpirole,microinfused
into the NI, on behavioural paradigms.
The RT-PCR shows that while the D2 receptor gene is transcribed
intomRNA in theNI, the D3 receptor gene is not. TheD2 (L+ S) receptor
antibody produced an ~100 kDa band corresponding to the dimeric
form of D2 receptors [31]. These dimers are unaffected by the reducing
and denaturing conditions of the western blot [9]. Notably, similar
bandswere observed in the caudate putamen, a region highly innervat-
ed by dopaminergic projections from the substantia nigra and known to
have rich D2 receptor expression [62,64]. Immunostaining conducted
with the same D2 antibody provides further evidence that D2
receptor-like immunoreactivity is found speciﬁcally at the base of
the 4th ventricle corresponding to the NI region. The D2S antibody
produced a strong ~41 kDa band in the NI and striatum indicating
the presence of the D2S isoform in both of these regions. However,
Fig. 7. Intra-NI administration of quinpirole (6 μg/0.1 μl) causes changes in behaviour in the novel environment-induced suppression of feeding paradigm. (A–I) Columns represent mean
of values and error bars represent SEM. *P b 0.05, **P b 0.01, ***P b 0.001 compared to vehicle treatment (sterile isotonic saline). Individual sample two-tailed t-test. N = 8–10.
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immunostaining/western blotting, the expression of D2L receptors
in the NI could not be investigated in the present study.
The immunoﬂuorescence co-expression experiments were carried
out with the D2S antibody due to the robust staining quality and
compatibility with the CRF1/2 and relaxin-3 antibodies. Strong D2S
receptor-like immunoreactivity was detected in the cell bodies of the
NI neurons comparable to previously reported labelling in other brain
regions [32,47]. The co-localisation of the D2S receptors with NeuN val-
idates the expression of these receptors in neuronal cells. CRF1 receptors
are densely expressed in the NI and considered amarker to delineate its
cytoarchitecture [16,38,51,56] while relaxin-3 expression is a feature
relatively unique to NI neurons [6,39]. The strong co-localisation of
D2S receptor-like immunoreactivity with CRF1 and relaxin-3 conﬁrms
its position in the NI. A limitation of the current study is that the precise
localisation of D2 receptors in the NI was only demonstrated by
immunostaining. This should be conﬁrmed by in situ with which
isoform-speciﬁc D2 receptor mRNA could be precisely localised in the
NI. While, the present study investigates the D2 and D3 receptors,
motivated by the c-fos inducing effects of antipsychotics in the NI [50],
additional studies aimed at other dopamine receptor subtypes will be
of interest.
The source of dopaminergic innervation to the NI is unlikely to be
from the midbrain dopaminergic structures, namely the ventral teg-
mental area and substantia nigra, as they do not signiﬁcantly project
to the NI [21]. Despite poor afferents from the VTA, the NI projects
strongly to the VTA providing a possible route for dopaminergic
feedback regulation [21]. Alternatively, dopamine input to the NIcould arise from the raphe nuclei which possess signiﬁcant numbers
of dopaminergic cells, speciﬁcally the median raphe which projects
robustly to the NI [21,44,58]. Similarly, the ventral periaqueductal
grey, which sends strong inputs to the NI, contains groups of dopa-
minergic cells [21,25,37]. To ascertain the source of dopamine inner-
vation to the NI, retrograde tracing combined with immunolabelling
of the dopamine transporter, tyrosine hydroxylase and dopamine
beta-hydoxylase should be conducted.
Based on previous literature, direct administration of ligands into
theNI is an aptmethod to study the functional properties of the nucleus.
Inactivation of the NI by direct lidocaine infusion during the Morris
water maze task indicated the structure's involvement in spatial and
working memory [42]. Similarly, a study conducted in our lab showed
that CRF infusion into the NI suppressed long-term potentiation,
reﬂecting the role of the NI in the stress-driven modulation of working
memory [16]. To study the functional relevance of the D2 receptors in
the NI, quinpirole wasmicro-infused into the NI and the behavioural ef-
fects were studied. Among the available D2 receptor agonists,
quinpirole (previously reported as LY 171555) has been relatively
well investigated in molecular, autoradiography, electrophysiological
and preclinical behavioural studies. It is a full agonist at the D2 receptor
and has been used to study effects of D2 receptor stimulation in vivo in
both rodents and primates by many investigators [1,12,14,18,23,28,
33–36,53]. Though quinpirole has ﬁve-fold stronger afﬁnity to D2
receptors than D3 receptors [19,54], we have made an effort to rule
out the D3 effects by using a dose (6 μg) that was recently reported to
be reasonably selective for D2 receptors over D3 [5]. Furthermore, the
RT-PCR conducted shows negligible expression of the D3 receptor
533J.R. Kumar et al. / Physiology & Behavior 151 (2015) 525–534gene in the NI. Hence the effects of quinpirole observed are most likely
mediated by the D2 receptors in the NI.
In the present study, intra-NI quinpirole infusion signiﬁcantly
suppressed locomotion-related parameters in the behavioural tests
conducted (home-cage monitoring and novel environment-induced
suppression of feeding). The home cage monitoring was carried out
using LABORAS, which is a sensitive behaviour data acquisition system
that utilizes a vibration sensitive platform to record and classify the
different kinds ofmovements exhibited by the rat [49]. Intra-NI infusion
of quinpirole signiﬁcantly suppressed distance travelled, duration of
time spent in locomotion and rearing duration, measured during the
ﬁrst 5 min and entire 2 h observation period. During the ﬁrst 5 min,
the behavioural effects observed are likely to be primarily due to the
effect of quinpirole on the NI D2 receptors. Therefore we focused
on the immediate locomotion and rearing suppression. Rearing is
frequently used to reﬂect both exploration and emotionality [57].
Based on the reduction in rearing behaviour, it is possible that NI D2
receptors could play a role in behavioural suppression.
Similar to the homecage monitoring, intra-NI quinpirole at the tested
dose suppressed locomotion in the novel environment-induced
suppression of feeding paradigm. In this paradigm, quinpirole altered
thigmotaxis, latency to reach the feed area, frequency of visits to feed
area, duration of time spent in feeding, latency to feed, quantity
of feed consumed and defecation. Although these results appear to
indicate an anxiogenic effect, the locomotor suppression effect of
quinpirole might have increased the latency to reach the feeding area
and reduced time spent in the feeding area, confounding the
hypophagic effects observed in this study. It is interesting to note that
feeding was not affected in the low stress home cage environment de-
spite suppression of locomotion. In fact, quinpirole infusion tended to
increase feeding duration (P = 0.0678) and frequency (P = 0.0618)
during the ﬁrst 5min. However, in the presumably high stress novel en-
vironment, intra-NI quinpirole infusion reduced feeding signiﬁcantly. It
is tempting to speculate that the D2 receptors in the NI modulate feed-
ing differentially in high and low stress environments, particularly since
there is high co-expression of CRF1 and D2S receptor-like immunoreac-
tivity in the NI.
Previous investigations have shown that administration of quinpirole
into various structures in dopaminergic circuitry affected locomotion and
rearing [3,8,13,15,60]. Similarly, the results of the present study support
the idea of D2 receptors in the NI being involved in locomotion. The be-
havioural tests in this investigationwere conducted immediately after in-
fusion of a small volume (0.1 μl) to limit diffusion to other areas. Although
the possibility of the drug diffusing to neighbouring structures cannot be
completely ruled out, the usage of a small volume of a speciﬁc agonist
(quinpirole) at a concentration previously proven to be effective at D2 re-
ceptors suggests that the hypolocomotor effects observed are very likely
to be due to action in the NI. The consistent hypolocomotion effect in-
duced by quinpirole infusion to the NI regardless of the paradigm points
to a functional role of these receptors in locomotion. Based on its
strong bidirectional connections to the median raphe and
interpeduncular nuclei, the NI was predicted to play a role in modu-
lating behavioural activity [21] and the present results lend support
to this hypothesis. The theta-modulating effects of the NI [43] could
be a possible mechanism through which the behavioural activity
levels are altered.
5. Conclusion
The current study reports RT-PCR and western blot evidence
for the expression of D2 receptor mRNA and protein, respectively,
in micro-punched tissue from the position of the NI. Additionally, D2
receptor-like immunoreactivity co-expresses with relaxin-3, CRF1 and
NeuN in the NI. Activation of these D2 receptors by microinfusion
of quinpirole into the NI caused hypolocomotion in the behavioural
paradigms tested. To the best of our knowledge, this is theﬁrst evidencefor the expression of a catecholamine receptor, the D2 receptor, in
the NI.
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